Abstract
Accurately estimating the prevalence and transmissibility of an infectious disease is an important task in genetic infectious disease epidemiology. However, generating accurate estimates of these quantities, that are informed by both epidemic time series and pathogen genome sequence data, is a challenging problem. While birth-death processes and coalescent-based models are popular methods for modelling the transmission of infectious diseases, they both struggle (for different reasons) with estimating the prevalence of infection.
Here we extended our approximate likelihood, which combines phylogenetic information from sampled pathogen genomes and epidemiological information from a time series of case counts, to estimate historical prevalence (in addition to the effective reproduction number). We implement this new method in a BEAST2 package called Timtam. In a simulation study our approximation is well-calibrated and can recover the parameters of simulated data.
To demonstrate how Timtam can be applied to real data sets we carried out empirical analyses of data from two infectious disease outbreaks: the outbreak of SARS-CoV-2 onboard the Diamond Princess cruise ship in early 2020 and poliomyelitis in Tajikistan in 2010. In both cases we recover estimates consistent with previous analyses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AEZ, BG and OGP are supported by The Oxford Martin Programme on Pandemic Genomics. AZ is supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme grant agreement no. 101001077.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available pathogen genomes and has a detailed listing of the data sources both in the manuscript and in the supplementary information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
a new analysis has been added
Data Availability
All data produced are available online as described in the manuscript
